ACTH(4-10) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-01. Anything still debated is marked as such rather than presented as settled.
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
| Property | Value | Notes |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Heptapeptide; ACTH(4-10) analog extended at C-terminus |
| Molecular mass | ~813.9 Da | Free peptide, unmodified |
| Appearance | White to off-white powder | Typical lyophilized solid |
| Solubility | Soluble in water and saline | Also soluble in common aqueous buffers |
| Storage (solid) | -20 °C, desiccated | Protect from moisture and repeated thawing |
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
==== Animal substances ==== Some animal parts used include cow gallstones, hornet nests, leeches, and scorpion. Other examples of animal parts include horn of the antelope or buffalo, deer antlers, testicles and penis bone of the dog, and snake bile. Some TCM textbooks still recommend preparations containing animal tissues, but there has been little research to justify the claimed clinical efficacy of many TCM animal products. 968+8956
Nevertheless, he had done enough to secure the empire's position, especially as the Umayyad Caliphate was undergoing another civil war. Beginning in 695, when Constantine's son Justinian II was first deposed, the empire entered an era of political instability that lasted for the next 22 years. While Justinian had stabilised the situation with the divided Arabs, the threat of the reconstituted caliphate was met by Leo III when he repelled the 717–718 siege, the first serious challenge against Arab expansion.
== Discovery and nomenclature == The antigen Thy-1 was the first T cell marker to be identified. Thy-1 was discovered by Reif and Allen in 1964 during a search for heterologous antisera against mouse leukemia cells, and was demonstrated by them to be present on murine thymocytes, on T lymphocytes, and on neuronal cells. It was originally named theta (θ) antigen, then Thy-1 (THYmocyte differentiation antigen 1) due to its prior identification in thymocytes (precursors of T cells in the thymus). The human homolog was isolated in 1980 as a 25kDa protein (p25) of T-lymphoblastoid cell line MOLT-3 binding with anti-monkey-thymocyte antisera. The discovery of Thy-1 in mice and humans led to the subsequent discovery of many other T cell markers, which is very significant to the field of immunology since T cells (along with B cells) are the major cellular components of the adaptive immune response.
=== Historical use in psychiatry and psychotherapy === LSD was subject to exceptional interest within the field of psychiatry in the 1950s and early 1960s, and Sandoz distributed LSD to researchers under the trademark name Delysid in an attempt to find a marketable use for it. During this period, LSD was controversially administered to hospitalised schizophrenic autistic children, with varying degrees of therapeutic success. It was said to have been tried in every type of mental disorder by 1960. LSD was also used in an attempt to cure homosexuality. Most of the early studies of LSD for psychiatric conditions were of very low quality, often lacking even control groups. In 1975, it was concluded that LSD showed little difference from placebo for most conditions. LSD-assisted psychotherapy was used in the 1950s and early 1960s by psychiatrists such as Humphry Osmond, who pioneered the application of LSD to the treatment of alcoholism, with promising results. Osmond coined the term "psychedelic," meaning "mind manifesting," as a term for LSD and related hallucinogens, superseding the previously held "psychotomimetic" model (in which LSD was believed to mimic schizophrenia). In contrast to schizophrenia, LSD can induce transcendent experiences, with lasting psychological benefit.
Sources: en.wikipedia.org
== Research == There is evidence that paroxetine may be effective in the treatment of compulsive gambling and hot flashes. Benefits of paroxetine prescription for diabetic neuropathy or chronic tension headache are uncertain. Although the evidence is conflicting, paroxetine may be effective for the treatment of dysthymia, a chronic disorder involving depressive symptoms for most days of the year. There is evidence to support that paroxetine selectively binds to and inhibits G protein-coupled receptor kinase 2 (GRK2) in mice with heart failure. Since GRK2 regulates the activity of the beta adrenergic receptor, which becomes desensitized in cases of heart failure, paroxetine (or a paroxetine derivative) could be used as a heart failure treatment in the future. Paroxetine has been identified as a potential disease-modifying osteoarthritis drug.
In June 2020, HHS announced an unusual agreement with Gilead in which HHS agreed to Gilead's wholesale acquisition price, HHS would continue to work together with state governments and drug wholesaler AmerisourceBergen to allocate shipments of remdesivir vials to American hospitals through the end of September 2020, and in exchange, during that three-month timeframe (July, August, and September), American patients would be allocated over 90% of Gilead's projected remdesivir output of more than 500,000 treatment courses. Absent from these announcements was any discussion of allocation of remdesivir production to the approximately 70 countries omitted from Gilead's generic drug licensing agreements—including much of Europe and countries as populous as Brazil, China, and Mexico—or the 127 countries listed on those agreements (during the time it will take for Gilead's generic licensees to ramp up their own production). As the implications of this began to sink in, several countries publicly confirmed the next day that they already had adequate supplies of remdesivir to cover current needs, including Australia, Germany, and the United Kingdom. In August 2020, the FDA broadened the Emergency Use Authorization (EUA) for remdesivir to include all hospitalized patients with suspected or laboratory-confirmed COVID‑19, irrespective of the severity of their disease. The Fact Sheet was updated to reflect the new guidance.
The rapid expansion of AI infrastructure has significant environmental implications. The energy demands of data centres are projected to grow substantially, potentially conflicting with the UK's net-zero targets and straining grid capacity. Additionally, the water consumption required for cooling data centres has raised sustainability concerns. Beyond domestic impacts, the global AI supply chain relies heavily on the extraction of critical minerals (such as cobalt and lithium) in the Global South, often associated with environmental degradation and human rights abuses. The development of AI models also depends on low-wage "ghost workers" in developing nations for data annotation and content moderation, prompting calls for mandatory human rights due diligence laws. While economic forecasts suggest AI could significantly boost UK GDP and productivity, realising these gains faces a "productivity paradox". Despite experimental evidence of productivity improvements, economy-wide data does not yet reflect an AI-driven boost, largely due to low adoption rates of bespoke systems among traditional businesses and the concentration of economic value among a small percentage of organisations. Furthermore, economists warn of "algorithmic rents", where dominant tech platforms extract wealth, potentially eroding the UK tax base and exacerbating market concentration. The UK's Digital Services Tax (DST) attempts to address this but remains controversial with the US government.
==== Recognized Institutions ==== These programs are offered by institutions recognized by the RCI. As of the 2025–26 cycle, recognized institutions for the M.Phil. program included major government hospitals, medical colleges, and universities across the country. Following the transition to the M.A. program, these institutions are expected to offer the new curriculum from the 2026–27 session onwards.
== Training == Some of the job skills and abilities that one needs to attain to be successful in this field of work include science, mathematics, reading comprehension, writing, and critical thinking. These skills are critical because of the nature of the experimental techniques of the occupation. One will also need to convey trends found in research in written and oral forms. A degree in biochemistry or a related science such as chemistry is the minimum requirement for any work in this field. This is sufficient for a position as a technical assistant in industry or in academic settings. A Ph.D. (or equivalent) is generally required to pursue or direct independent research. To advance further in commercial environments, one may need to acquire skills in management. Biochemists must pass a qualifying exam or a preliminary exam to continue their studies when receiving a Ph.D. in biochemistry. Biochemistry requires an understanding of organic and inorganic chemistry. All types of chemistry are required, with emphasis on biochemistry, organic chemistry and physical chemistry. Basic classes in biology, including microbiology, molecular biology, molecular genetics, cell biology, and genomics, are focused on. Some instruction in experimental techniques and quantification is also part of most curricula. In the private industries for businesses, it is imperative to possess strong business management skills as well as communication skills. Biochemists must also be familiar with regulatory rules and management techniques.
Sources: en.wikipedia.org
Many proteins are composed of several protein domains, i.e. segments of a protein that fold into distinct structural units. Domains usually have specific functions, such as enzymatic activities (e.g. kinase) or they serve as binding modules.
==== Broad-spectrum antibiotics ==== This group of antibiotics is called "broad-spectrum" because they are active against a wide range of Gram-negative bacteria such as Escherichia coli and Salmonella typhi, for which penicillin is not suitable. However, resistance in these organisms is now common.
In the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Kight Reidlich cloned a giant version of Abrella that he kept on Planet Highgord to help him fight the Dekarangers. However, Clone Abrella is killed by Dekaranger Robo piloted by Deka Break. Throughout the series, Abrella pilots the following Kaijuki as part of his schemes:
=== Domestic === The January 2026 escalation was cited by Danish prime minister Mette Frederiksen as a factor behind her decision to call snap elections, stating that "We must define our relationship with the U.S. We must arm ourselves to ensure peace on our continent. We must keep Europe together". Opinion polls indicated that the crisis boosted the popularity of Frederiksen's party, the Social Democrats.
Sources: en.wikipedia.org
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.
Its sequence corresponds to the 4-10 region of corticotropin extended by three residues. This fragment lacks the region responsible for adrenal steroid release, so it is explored for neural rather than hormonal effects. The relationship explains the compound's classification among ACTH-derived peptides.
It holds approval in Russia for several neurological indications as a nasal spray or drop formulation. Regulatory agencies in the United States and the European Union have not approved it. Products sold elsewhere are generally labeled for research use only.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.